BioSpace News Archive

Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials.

Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.

The cash infusion will support the growth of its manufacturing capabilities in the US and the UK and the demands for gene therapies, antibodies, and vaccines such as COVID-19.

The new funding will be used to advance the company’s potential best-in-class epidermal growth factor receptor tyrosine kinase inhibitor furmonertinib, a lung cancer treatment that has been licensed from Allist Pharmaceuticals.

Aditum Bio today announced the formation of Ancora Bio, a portfolio company developing a new therapy for treatment-resistant depression.

Fact MR - A Market Research and Competitive Intelligence Provider: The global newborn screening market outlook remains positive with Fact MR projecting it to surpass a valuation of US$ 1 Bn by the end of 2031.

Fact MR- A Market Research and Competitive Intelligence Provider: Fact MR presents an impressive compound houttuynia market growth outlook for the assessment period from 2021 to 2031.

According to the report, the global radiopharmaceutical market was valued at US$ 3.6 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced clinical data from a pilot study on Yselty® for the treatment of severe adenomyosis was presented at the European Society of Human Reproduction and Embryology Virtual 37th Annual Meeting, being held June 26-July 1, 2021.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the company has entered into a sales agreement with Cantor Fitzgerald & Co., acting as sales agent, to offer American Depositary Shares, each representing six shares with no nominal value through an “at-the-market” offering program.